德克斯特罗米多芬过量服用与耐火状态和可逆的头骨神经反射损失:一个案例报告
Akifumi Okamoto1, Naoki Yonezawa2, Kazuhiro Yoshizawa2
1Department of Pharmacy, Yokohama City Minato Red Cross Hospital, Yokohama, Kanagawa, Japan.
The American journal of case reports
|March 13, 2025
概括
大量的德克斯特罗梅索芬过量服用可能会导致严重的神经问题,如发作和神经反射损失. 迅速的重症监护对于生存和从这种毒性中恢复至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
- 神经学 神经学
背景情况:
- 德克斯特罗梅索芬是一种常见的抗咳药物,在推剂量下具有一般安全的特征.
- 过度使用德克斯特罗梅索芬可以导致严重的不良反应,但详细的病例报告与药理动力学数据是有限的.
- 了解严重过量情况对于临床管理和患者安全至关重要.
研究的目的:
- 报告一例罕见的大规模德克斯特罗梅索芬过量用药的病例,并进行详细的药理动力学分析.
- 调查严重德克斯特罗梅索芬毒性的临床表现和管理.
- 阐明德克斯特罗梅索芬与其代谢物德克斯特罗索芬在过量毒性的作用.
主要方法:
- 一个21岁的精神分裂症女性患者的病例报告,她摄入了大量的德克斯特罗米多芬.
- 临床观察和密集的支持性护理,包括内内管和抗治疗.
- 对德克斯特罗梅索芬和德克斯特罗梅索芬的血清度进行连续监测.
主要成果:
- 这位患者在摄入20,280毫克德克斯特罗梅索芬后出现了耐火状态和可逆的神经反射损失.
- 血清中德克斯特罗梅索芬水平明显升高,而德克斯特罗梅索芬水平保持在治疗范围之内.
- 患者的病情稳定,在重症监护中完全康复,没有长期的后果.
结论:
- 大量的德克斯特罗梅索芬过量服用可能会导致严重的,可能致命的神经系统并发症,包括状态.
- 药物动力学数据表明,在这种情况下,德克斯特罗梅索芬本身,而不是其代谢物,主要是造成毒性的原因.
- 有效的管理依赖于密集的支持性护理,影响新陈代谢的因素可以影响结果.
相关概念视频
Desensitization and Tachyphylaxis
1.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.4K
Anticholinesterase Agents: Poisoning and Treatment
767
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
767
Depolarizing Blockers: Mechanism of Action
1.1K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.1K
Depolarizing Blockers: Pharmocokinetics
299
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
299
Skeletal Muscle Relaxants: Adverse Effects
327
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
327
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
![Quantitative [18F]-Naf-PET-MRI Analysis for the Evaluation of Dynamic Bone Turnover in a Patient with Facetogenic Low Back Pain](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58491.jpg&w=3840&q=50)

